(Q38181208)

30 August 2017

title

Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents (English)

1 reference

30 August 2017

Juan Tamargo

1

0 references

Luis Miguel Ruilope

object named as

Luis M Ruilope

series ordinal

3

0 references

author name string

Julian Segura

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

23 January 2014

1 reference

Expert Opinion on Pharmacotherapy

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

605-621

1 reference

Use of diuretics in patients with hypertension

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Loop diuretics: from the Na-K-2Cl transporter to clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

The Na-K-Cl cotransporter of secretory epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

NKCC1 and hypertension: a novel therapeutic target involved in the regulation of vascular tone and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Vascular effects of loop diuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Ethnic differences in renal responses to furosemide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Anti-aldosteronergic effect of torasemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Torasemide in chronic heart failure: results of the TORIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Absorption of High Dose Furosemide (Frusemide) in Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Comparison of loop diuretics in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Aldosterone: effects on the kidney and cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Low-dose spironolactone in the management of resistant hypertension: a surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

The role of spironolactone in the treatment of patients with refractory hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Cardiovascular outcomes in patients with primary aldosteronism after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Efficacy of low-dose spironolactone in subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Effects of eplerenone versus losartan in patients with low-renin hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Aldosterone in the development and progression of renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Aldosterone antagonist improves diastolic function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Amiloride, a specific drug for hypertension in black people with T594M variant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Aldosterone synthase inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Increase in plasma aldosterone during prolonged captopril treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Drug-Induced Lithium Toxicity in the Elderly: A Population-Based Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.879117

10.1517/14656566.2014.879117

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference